Hansa Medical acquires rights to cancer immunotherapy using antibody-modulating enzymes
Hansa Medical AB (publ) today announced the acquisition of UK based Immago Biosystems Ltd, a University of Oxford-spinout focused on the enhancement of antibody based cancer therapies using antibody-modulating enzymes.The founders of Immago Biosystems, Dr Chris Scanlan and Dr Max Crispin at the Glycoprotein Therapeutics Laboratory, at the University of Oxford, have discovered that IgG-antibody modulating enzymes can enhance the efficacy of antibody based cancer treatments. Together with their colleague, Dr Kavitha Baruah, they formed Immago Biosystems Ltd to help bring these concepts to the